State of the Art Biomedical Services
CryoLife, Inc. is one of the world’s leading contemporary medical device companies; providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries. Since the Company’s inception in 1984, it is estimated that its products and tissues have been implanted in about 900,000 patients worldwide.
Products & Services
BioGlue Surgical Adhesive
The leading surgical adhesive used in cardiovascular surgery.
AV access solution to reduce catheter dependency.
PerClot Topical is a medical device composed of absorbable polysaccharide granules and delivery applicators.
Transmyocardial revascularization (TMR) is a clinically proven laser therapy procedure for chronic angina patients.
Aortic and pulmonary homografts for cardiac reconstruction.
Allografts for AV access, peripheral bypass, and infected fields.
SynerGraft is CryoLife's patented decellularization technology.
ProCol Vascular Bioprosthesis
A natural biological graft derived from a bovine mesenteric vein that provides vascular access for ESRD hemodialysis patients.
International Products & Services
News & Events
CryoLife Acquires Distribution Rights and Purchase Option for Genesee BioMedical's PhotoFix™ Bovine Pericardial Patch
August 7, 2014
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has acquired the distribution rights to PhotoFix, a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde from Genesee BioMedical, Inc., a Denver, Colorado-based manufacturer of cardiac surgery instruments and devices.
CryoLife to Present at 34th Annual Canaccord Genuity Growth Conference
August 5, 2014
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at the InterContinental Boston Hotel.